Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ebola in eye
http://http://mobile.nytimes.com/201...referrer=&_r=0
ATLANTA — When Dr. Ian Crozier was released from Emory University Hospital in October after a long, brutal fight with Ebola that nearly ended his life, his medical team thought he was cured. But less than two months later, he was back at the hospital with fading sight, intense pain and soaring pressure in his left eye.
Test results were chilling: The inside of Dr. Crozier’s eye was teeming with Ebola.
His doctors were amazed. They had considered the possibility that the virus had invaded his eye, but they had not really expected to find it. Months had passed since Dr. Crozier became ill while working in an Ebola treatment ward in Sierra Leone as a volunteer for the World Health Organization. By the time he left Emory, his blood was Ebola-free. Although the virus may persist in semen for months, other body fluids were thought to be clear of it once a patient recovered. Almost nothing was known about the ability of Ebola to lurk inside the eye.
Despite the infection within his eye, Dr. Crozier’s tears and the surface of his eye were virus-free, so he posed no risk to anyone who had casual contact with him.
Dr. Crozier's eyes were examined again on March 27 by Dr. Yeh at Emory Eye Center in Atlanta. Eye troubles are common among Ebola survivors.
KEVIN LILES FOR THE NEW YORK TIMES
More than a year after the epidemic in West Africa was recognized, doctors are still learning about the course of the disease and its lingering effects on survivors. Information about the aftermath of Ebola has been limited because past outbreaks were small: no more than a few hundred cases, often with death rates of 50 percent to 80 percent. But now, with at least 10,000 survivors in Guinea, Liberia and Sierra Leone, patterns are emerging.
A Secondary Problem
Dr. Crozier, 44, ruefully calls himself a poster child for “post-Ebola syndrome”: Besides eye trouble, he has had debilitating joint and muscle pain, deep fatigue and hearing loss. Similar problems are being reported in West Africa, but it is not clear how common, severe or persistent they are. There have even been reports of survivors left completely blind or deaf, but these accounts are anecdotal and unconfirmed
From March 2015...Aethlon Medical’s Adaptive Dialysis-like Affinity Platform Technology, or ADAPT for short, is the foundation for their flagship product, called the Hemopurifier®, an extracorporeal filtration device that has been shown to selectively and rapidly remove a wide array of viral pathogens, including HIV, and tumor-secreted exosomes from the circulatory system. The company is furthest along with Hepatitis C research. Aethlon disclosed late in February that it has partnered with contract research organization DaVita Clinical Research, a subsidiary of DaVita HealthCare Partners, to provide clinical management services to support additional upcoming clinical trials of the Hemopurifier in end-stage renal disease patients infected with Hepatitis C virus.
Aethlon’s medical device technology is complemented by the exosome expertise of its subsidiary Exosome Sciences Inc. From a broad perspective, research of exosomes, nano-size extracellular vesicles secreted by most every somatic cell and found in bodily fluids, is a rapidly emerging science that leading institutions, such as MD Anderson, have suggested could lead to revolutionary diagnostic tests. While MD Anderson is focused on oncology applications, recent discoveries indicate that exosomes could play a key role in diagnosing, and perhaps treating, degenerative brain conditions.
Aethlon and Exosome Sciences have recently made a potential breakthrough by successfully isolating brain-specific biomarkers in the blood that are associated with a variety of neurodegenerative disorders. Because exosomes can pass through the blood/brain barrier, the microscopic cargo haulers can carry vital information about neurodegenerative conditions happening in the brain. The companies’ research identified exosomes carrying brain-specific markers, including tau, beta-amyloid and other proteins. Tau is of particular interest in CTE research as the accumulation of tau is a hallmark of CTE, a disease often identified in soldiers exposed to blast injury and attributed to suicides of high-profile athletes Junior Seau, Dave Duerson and Andre Waters that can only be officially diagnosed in an autopsy.
The potential to conduct a simple blood test to identify proteins that could implicate a condition like CTE or dementia at an early stage presents an opportunity for a new dynamic to identify and manage life-threatening and debilitating diseases. It also opens the door for innovative approaches as cornerstones to a new paradigm of research. This sort of research takes time, there is no denying that, but thanks to the efforts of organizations like Boston University and UCLA, funding support from the National Institute of Health, the National Football League and General Electric (GE) and the pioneering efforts of companies like Neuralstem and Aethlon Medical, it’s moving faster than ever before.
http://finance.yahoo.com/news/breakthroughs-horizon-cte-other-neurodegenerative-171500718.html
thanks
Well I suppose we really don't know what we don't know, in terms of catalysts--nobody saw Ebola coming as a catalyst last fall, and that was huge.
16-Mar-2015
Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On March 12, 2015, Aethlon Medical, Inc. ("we") entered into a modification of our contract with the Defense Advanced Research Projects Agency, part of the Department of Defense. We entered into the initial contract on September 30, 2011. The Defense Advanced Research Projects Agency entered into the contract modification in an effort to accelerate our production of the Aethlon Hemopurifier? by modifying specific milestones we must achieve under the contract as follows:
? Milestone M6 under year 3 of the contract:
o Modified milestone: Define Aethlon's GMP manufacturing process [for the Aethlon Hemopurifier?] and revise and upgrade Aethlon's quality procedures and policies to the current state of the art.
o Previous milestone: Demonstrate the safety of at least one prototype device within an optimized fluidic circuit architecture preventing clotting in a 24-hour experiment in vivo at a blood flow rate of 200 ml/min using either pigs or dogs.
? Milestone 2.5.1.1 under year 4 of the contract:
o Modified milestone: Complete Aethlon's GMP procedure [for the Aethlon Hemopurifier?] and establish and maintain all GMP documentation for the company.
o Previous milestone: Develop additional optimized configuration(s) of hemopurification device(s) that contain(s) a combination of hemofilters, plasma filters, and affinity columns.
? Milestone M11 under year 4 of the contract:
o Modified milestone: Develop a strategic plan for developing an alternate method of producing GNA [Galanthus nivalis agglutinin, the affinity lectin immobilized within the Aethlon Hemopurifier?] by cloning the gene into an alternate vector and identify potential partners for such production.
o Previous milestone: Demonstrate the safety of an additional prototype device within an optimized fluidic circuit architecture preventing clotting in a 24-hour experiment in vivo at a blood flow rate of 200 ml/min using either pigs or dogs.
The contract is priced on a fixed-price basis. The contract modification did not change the fixed payments due to us upon our achievement of the milestones.
LOL yea that's what'll happen
Good post...point#3 I believe is where the mystery will be revealed...we sell another 10-20% in ESI to raise whatever additional cash is required...though I really wish he would issue more stock of AEMD...too few shares out there now.
Nice letter from Chan--I guess he doesn't know the least effective timing for communicating to the Street is on a Friday.
Yea nice job by him to find this...looks interesting
Ok no worries--yes, that's two different processes--we don't qualify for NASDAQ...yet :)
dj where do you see uplisting to NASDAQ?
"Just not willing to gamble so much i had in I'll probably buy back at much, much less"
Haha....right, the operative word there is probably
what news are you referring to?
thanks dj
thanks bk
Idk...how much is he getting paid?
Hopester I'm familiar with that whole thing, I just don't believe anything Adam F says. In my opinion, he works under the table for one or some of the market makers in the stock, they got caught way short with the run-up to 72 cents, and he unleashed that statement in his column, raising doubt and all heck ensued.
Nobody knows the truth, but I'd believe JJ before Adam F. andyday.
I'm not certain it was ever clarified whether or not it was requested--the Nebraska spokesman played dumb or was uninformed...anyways, we'll see.
I'm not certain it was ever clarified whether or not it was requested--the Nebraska spokesman played dumb or was uninformed...anyways, we'll see.
I doubt they would release news of unit shipment, given how that news blew up in their face last year when shipped to Nebraska.
What part don't you get?
Speculation--they will float a secondary soon to fund ESI endeavors/expansion. Sell another 3 million or so shares to bring us closer to 10 million.
We need more shares oustanding now--6 million and change will not be attractive to an institution as not enough liquidity to get in and out without effecting stock price.
Haha can't leave///"no business plan" You sound informed as always
They didn't specify but minimum market cap is one they prob don't meet
They don't currently meet all the listing requirements. What more is to come?
Hope you mean it this time
Never mind, I see we are still waiting on that
Apologize if already covered, but did we get a payable date yet for the spin-off?
What was interesting about it?
thanks for the updates hopester
thanks
Never woulda thunk we'd see 16k shares traded at mid-day two weeks before the end of March.
No news? You guys mean no official pr from the company? I assume you know about the filing yesterday. Yea not sure why no news release about the DARPA contract, should be one imo.
thank you!!
So hopester, has the patient recovered or more time required for a diagnosis?
You don't know anything about me. Please whine about your bad investment to somebody who cares.
Hmmmm....another salient point Sir skydog, how can one argue with that?
Apologies, I see you were speaking about yesterday
wow amazing fill, high of the day is 6.52 lol
omg dude please sell and buy another stock and whine on that board